The final step to establish the drug's long-term effectiveness and safety is a phase 3 trial, and efforts to launch that pivotal trial are soon to be underway with an industry partner. In AVS ...

AVS recently completed a 30-day follow-up with those clinical trial participants, who reported no major medical events. This new funding will be put toward completing clinical trials for FDA approval ...

BOSTON--(BUSINESS WIRE)--AVS, an early-stage medical device company focused on safely and effectively treating severely calcified arterial disease with its PIVL™ therapy, announced today that it ...